Streetbeat News

MODD

Modular Medical, Inc.

Industry

Medical - Devices

Modular Medical, Inc., a development stage medical device company, focuses on the design, development, and commercialization of insulin pumps using technology to enhance pump adoption in the diabetes marketplace. The company is headquartered in San Diego, California.

Open

2.10

Mkt cap

72M

Volume

115K

High

2.14

P/E Ratio

-3.04

52-wk high

2.65

Low

2.05

Div yield

N/A

52-wk low

1.00

The article reports on the performance of health care stocks in Monday's after-market session, highlighting significant gainers and losers. Notably, Aesthetic Medical Intl, Harrow, and Vaxart experienced upward movements, attributed to recent earnings releases for some. Conversely, Augmedix, Akoya Biosciences, and Calidi Biotherapeutics saw notable declines, also influenced by their earnings reports.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 8:31 pm

In Wednesday's after-market session, health care stocks saw significant movements. Avalo Therapeutics (AVTX) led the gainers with a 215.8% increase to $15.0, while Strata Skin Sciences (SSKN) led the losers with a 12.5% decrease to $0.39. Other notable movers included Fresh2 Group (FRES), Biora Therapeutics (BIOR), and GlycoMimetics (GLYC), with their stock prices also experiencing changes due to various factors including Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 8:31 pm

Benchmark analyst Bruce Jackson reiterates a Speculative Buy rating on Modular Medical (NASDAQ:MODD) and maintains a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 2:09 pm

In Monday's intraday session, several healthcare stocks experienced significant movements. Notably, Applied Therapeutics, Universe Pharmaceuticals, Modular Medical, Equillium, Phathom Pharmaceuticals, and Sangamo Therapeutics saw substantial gains, with increases ranging from 31.42% to 42.5%. On the downside, AMN Healthcare Services, BioSig Technologies, Cross Country Healthcare, Inventiva, T2 Biosystems, and Pacific Biosciences faced declines between 14.02% and 20.7%. These movements were influenced by recent earnings reports and market valuations.

Portfolio Pulse from Benzinga Insights

February 19, 2024 | 5:30 pm

In Friday's intraday session, several healthcare stocks showed significant movement. OneMedNet, Applied Therapeutics, and Modular Medical were among the top gainers, with shares rising up to 91.2%, 28.53%, and 24.58% respectively. On the losing side, AMN Healthcare Services, Cross Country Healthcare, and Inventiva saw declines of up to 18.9%. Earnings releases influenced some of the stock movements.

Portfolio Pulse from Benzinga Insights

February 16, 2024 | 5:31 pm

Modular Medical has announced a public offering of 9,090,910 shares at $1.10 each, led by Manchester Explorer, L.P. and including other institutional investors. The company also granted an option for the purchase of up to 1,321,989 additional shares.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 6:57 am

Modular Medical has announced a proposed public offering. This move is aimed at raising capital, potentially for expansion or operational purposes. The specifics of the offering, such as the number of shares to be offered and the price range, have not been disclosed.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 9:46 pm

In Thursday's after-market session, several healthcare stocks showed notable movements. Gainers included China Pharma Holding, SenesTech, Lucy Scientific Discovery, OneMedNet, Universe Pharmaceuticals, and Vaxxinity with increases ranging from 4.99% to 12.7%. Losers were led by Modular Medical, Adial Pharmaceuticals, Pacific Biosciences, Nuwellis, Perspective Therapeutics, and Onconova Therapeutics, with declines between 4.39% and 16.3%. Key financial updates were noted for Lucy Scientific Discovery, Modular Medical, and Pacific Biosciences.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 9:31 pm

In Tuesday's pre-market session, several healthcare stocks showed significant movement. KalVista Pharma, Jin Medical International, and Biodexa Pharmaceuticals were among the top gainers, with increases of 31.5%, 25.75%, and 21.37% respectively. On the losing end, Sientra, G1 Therapeutics, and Ensysce Biosciences saw declines of 51.3%, 43.98%, and 17.39% respectively. Beyond Air reported a decline following their Q3 earnings release.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 1:06 pm

Modular Medical has announced the submission of a 510(k) application for its MODD1 Insulin Pump to the FDA, a significant regulatory step that could lead to market approval.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 11:04 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.